4 - Erasca, Inc. (0001761918) (Issuer)

4 - Erasca, Inc. (0001761918) (Issuer)

4 - Erasca, Inc. (0001761918) (Issuer)

4 - Erasca, Inc. (0001761918) (Issuer)

4 - Erasca, Inc. (0001761918) (Issuer)

4 - Erasca, Inc. (0001761918) (Issuer)

4 - Erasca, Inc. (0001761918) (Issuer)

4 - Erasca, Inc. (0001761918) (Issuer)

4 - Erasca, Inc. (0001761918) (Issuer)

4 - Erasca, Inc. (0001761918) (Issuer)

10-K - Erasca, Inc. (0001761918) (Filer)

8-K - Erasca, Inc. (0001761918) (Filer)

144 - Erasca, Inc. (0001761918) (Subject)

8-K - Erasca, Inc. (0001761918) (Filer)

8-K - Erasca, Inc. (0001761918) (Filer)

424B5 - Erasca, Inc. (0001761918) (Filer)

8-K - Erasca, Inc. (0001761918) (Filer)

424B5 - Erasca, Inc. (0001761918) (Filer)

8-K - Erasca, Inc. (0001761918) (Filer)

144 - Erasca, Inc. (0001761918) (Subject)

Encouraging early clinical activity observed during ERAS-0015 dose escalation, including ongoing responses across multiple RAS-mutant tumors with favorable safety, tolerability, and pharmacokinetics Phase 1 monotherapy data for ERAS-0015 expected in H1 2026 and for ERAS-4001 in H2 2026 Successfully completed $259 million upsized financing in January Robust balance sheet with pro forma cash, cash equivalents, and marketable securities of $434 million expected to fund operations into H2 2028 SAN DIEGO, March 12, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for

Worldwide rights position Erasca to advance ERAS-0015 through a unified global development strategy ERAS-0015's promising early clinical data underscore its potential to be a best-in-class RAS-targeting agent Initial Phase 1 monotherapy data for ERAS-0015 expected in H1 2026 SAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the exercise of its option to expand the existing license agreement with Joyo Pharmatech Co., Ltd. (Joyo) to include China, Hong Kong, and Macau, which will

ERAS-0015, a pan-RAS molecular glue, will be evaluated in combination with PRMT5 inhibitor vopimetostat Tango will sponsor the clinical trial and Erasca will supply ERAS-0015 at no cost SAN DIEGO, March 05, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced a clinical trial collaboration and supply agreement (CTCSA) with Tango Therapeutics, Inc. (NASDAQ:TNGX, "Tango")) to evaluate Erasca's pan-RAS molecular glue, ERAS-0015, with Tango's PRMT5 inhibitor, vopimetostat (TNG462). "We've disclosed encoura

The issued patent provides intellectual property protection for ERAS-4001 and related compositions until at least 2043 Expands Erasca's diversified IP portfolio for RAS-driven cancers Initial Phase 1 monotherapy data expected for ERAS-0015 in 1H and for ERAS-4001 in 2H 2026 SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that the U.S. Patent and Trademark Office has issued Patent No. 12,552,813, titled "Heterocyclic Substituted Pyrimidopyran Compound And Use Thereof." The paten

VANCOUVER, British Columbia, Feb. 17, 2026 (GLOBE NEWSWIRE) -- USANewsGroup.com News Commentary – The FDA's accelerated approval framework continues to deliver measurable population health gains, with a January 2026 analysis in Cancer Research Communications confirming that drugs cleared through the program improved real-world progression-free survival in 65% of solid tumor indications studied, with none performing worse than the existing standard of care[1]. That track record is fueling a concentrated push among clinical-stage oncology companies toward registration-directed study designs in high-unmet-need tumor types, as demonstrated by Oncolytics Biotech Inc. (NASDAQ:ONCY), Incyte (NASD

SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that management will participate in the following investor conferences in February 2026 and will also participate in one-on-one investor meetings at each of these conferences. Guggenheim Emerging Outlook: Biotech Summit 2026 (February 11-12, 2026) Location: New York, NY Format: Fireside Chat Date and Time: Thursday, February 12, 1:00 pm Eastern Time Oppenheimer 36th Annual Healthcare Life Sciences Conference (February 25-26, 202

SAN DIEGO, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that it has closed its previously announced upsized public offering of 25,875,000 shares of its common stock, including 3,375,000 shares sold pursuant to the underwriters' full exercise of their option to purchase additional shares. The shares of common stock were sold to the public at a price of $10.00 per share. The gross proceeds to Erasca from the offering, before deducting the underwriting discounts and commissions and other off

SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the pricing of an upsized public offering of 22,500,000 shares of its common stock. The shares of common stock are being sold to the public at a price of $10.00 per share. All of the shares of common stock to be sold in the public offering are to be sold by Erasca. The gross proceeds to Erasca from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be $225.0 million.

SAN DIEGO, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that it intends to offer and sell, subject to market and other conditions, $150.0 million of shares of its common stock in a proposed underwritten public offering. All of the shares of common stock to be sold in the proposed offering are being offered by Erasca. In addition, Erasca intends to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of shares of its common stock. There can be no assurance a

Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Jan. 16, 2026 /PRNewswire/ -- Equity Insider News Commentary – The precision medicine sector is undergoing a structural realignment toward platform-based biologics, as the market prepares to surge from $138 billion this year to over $537 billion by 2035[1]. This shift marks the end of "one-size-fits-all" treatments, as investors rotate capital into modular systems designed to hunt multiple cancer targets at once. This secular transition is creating massive opportunities for specialized platforms that can scale across high-prevalence killers like lung, breast, and pancreatic cancers, led by GT Biopharma, Inc. (NASDAQ:GTBP), ImmunityBio (NA

4 - Erasca, Inc. (0001761918) (Issuer)

4 - Erasca, Inc. (0001761918) (Issuer)

4 - Erasca, Inc. (0001761918) (Issuer)

4 - Erasca, Inc. (0001761918) (Issuer)

4 - Erasca, Inc. (0001761918) (Issuer)

Mizuho resumed coverage of Erasca with a rating of Outperform and set a new price target of $16.00

Piper Sandler initiated coverage of Erasca with a rating of Overweight and set a new price target of $5.00

Stifel initiated coverage of Erasca with a rating of Buy and set a new price target of $4.00

BofA Securities downgraded Erasca from Buy to Underperform

Morgan Stanley downgraded Erasca from Overweight to Equal-Weight and set a new price target of $2.00

Raymond James initiated coverage of Erasca with a rating of Outperform and set a new price target of $5.00

Jefferies initiated coverage of Erasca with a rating of Buy and set a new price target of $6.00

CapitalOne initiated coverage of Erasca with a rating of Overweight and set a new price target of $8.00

BofA Securities downgraded Erasca from Buy to Neutral and set a new price target of $6.00 from $11.00 previously

H.C. Wainwright initiated coverage of Erasca with a rating of Buy and set a new price target of $10.00

USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 30, 2025 /PRNewswire/ -- USA News Group News Commentary – The oncology landscape is being pulled in two directions. On one hand, U.S. cancer death rates continue to decline. On the other, global cases are expected to rise sharply—while early-onset diagnoses in younger patients are climbing at a troubling pace. At the same time, proposed federal budget cuts threaten to slash funding for the National Cancer Institute by up to 40%, raising concerns about the future of publicly funded research. With public resources under pressure, much of the innovation burden is shifting to the private sector, where a

SAN DIEGO, April 27, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the appointment of Jean Liu to its board of directors and to its audit committee. Ms. Liu brings over 20 years of professional experience advising biopharmaceutical companies on corporate, intellectual property, compliance, and general legal matters. "Jean Liu has been a seasoned executive with Seagen during its transformation into a leading global, multiproduct oncology company, and she also is one of the most strategic busine

Lisa Tesvich-Bonora appointed as Chief People Officer Robert Shoemaker promoted to Senior Vice President of Research SAN DIEGO, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the appointment of Lisa Tesvich-Bonora as Chief People Officer and the promotion of Robert Shoemaker to Senior Vice President of Research. "I am thrilled to welcome Lisa to the Erasca family. With over two decades of experience in creating collaborative and engaging environments where employees can thrive, she bring

Pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 are potent, oral inhibitors with potential best-in-class profiles in RASm solid tumors Pipeline prioritization and workforce restructuring sharpens focus on programs targeting the highest unmet needs and with highest probability of success Priced concurrent $160 million equity offering Erasca to host conference call and webcast Friday, May 17, 2024 at 8:30 am ET SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today anno

Median OS of 13-14 months for naporafenib plus trametinib in pooled analysis of patients with NRASm melanoma Strengthened balance sheet with private placement financing from high-quality new and existing healthcare-focused investors Pro forma cash, cash equivalents, and marketable securities of $334 million is expected to fund operations into H2 2026 SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today provided business updates and reported financial results for the fiscal quarter ended March

Gained global registrational clarity for naporafenib and achieved key clinical milestones for naporafenib, ERAS-007, and ERAS-801 Multiple data readouts expected in 2024 for naporafenib (SEACRAFT-1), ERAS-007 (HERKULES-3), and ERAS-801 (THUNDERBBOLT-1) and planned initiation of pivotal SEACRAFT-2 trial Robust balance sheet with cash, cash equivalents, and marketable securities of $322 million as of December 31, 2023 Erasca to host R&D update conference call and webcast Thursday, March 28, 2024 at 8:30 am ET SAN DIEGO, March 27, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and comm

Concurrent $100 million equity offering Naporafenib has a potential first-in-class and best-in-class profile in multiple RAS/MAPK pathway-driven tumors Pivotal-ready asset has been dosed in over 500 patients to date and expands Erasca's addressable population Erasca to host conference call and webcast today at 8:30 am ET SAN DIEGO, Dec. 09, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced it has entered into an exclusive worldwide license agreement with Novartis (NYSE:NVS) for naporafenib, a Phase

SC 13G/A - Erasca, Inc. (0001761918) (Subject)

SC 13G/A - Erasca, Inc. (0001761918) (Subject)

SC 13G - Erasca, Inc. (0001761918) (Subject)

SC 13G/A - Erasca, Inc. (0001761918) (Subject)

SC 13G - Erasca, Inc. (0001761918) (Subject)

SC 13G - Erasca, Inc. (0001761918) (Subject)

SC 13G - Erasca, Inc. (0001761918) (Subject)

SC 13G - Erasca, Inc. (0001761918) (Subject)

SC 13G/A - Erasca, Inc. (0001761918) (Subject)

SC 13D/A - Erasca, Inc. (0001761918) (Subject)